hypertension

News

ACC25: Mineralys' uncontrolled hypertension drug aces trial

Mineralys looks odds on to become the first drug developer to bring an aldosterone synthase inhibitor to market for uncontrolled hypertension.

News

When licensing deals go bad - Novo sues KBP Bio for $830m

Novo Nordisk lawsuit claims KBP concealed clinical data ahead of a $1.3bn licensing deal for blood pressure drug candidate ocedurenone.

News

Study backs Closed Loop's drug+digital blood pressure plan

Closed Loop Medicine's smartphone app for blood pressure monitoring has shown proof-of-concept in the Cure-19 study.

News

Novo sheds kidney drug licensed for $1.3bn a year ago

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.

R&D

A spectrum of obesity requires precision

Obesity is a hot topic, and a focal research area, in the twentieth century.

Sales & Marketing

Company Profile: Aktiia

Hypertension is known to be one of the most prevalent chronic health conditions globally.

ACC25: Mineralys' uncontrolled hypertension drug aces trial

When licensing deals go bad - Novo sues KBP Bio for $830m

Study backs Closed Loop's drug+digital blood pressure plan

Novo sheds kidney drug licensed for $1.3bn a year ago

A spectrum of obesity requires precision

Company Profile: Aktiia

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

hypertension

Editor's Picks